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Insights into the molecular basis and the temporal evolution of neurotoxic-
ity in prion disease are increasing, and 
recent work in mice leads to new avenues 
for targeting treatment of these disor-
ders. Using lentivirally mediated RNA 
interference (RNAi) against native prion 
protein (PrP), White et al. report the first 
therapeutic intervention that results in 
neuronal rescue, prevents symptoms and 
increases survival in mice with estab-
lished prion disease.1 Both the target and 
the timing of treatment here are crucial 
to the effectiveness of this strategy: the 
formation of the neurotoxic prion agent 
is prevented at a point when diseased 
neurons can still be saved from death. 
But the data also give new insights into 
the timing of treatment in the context 
of the pattern of spread of prion infec-
tion throughout the brain, with implica-
tions for developing the most effective 
treatments.
This perspective considers develop-
ments in the field that led to the rationale 
for targeting endogenous prion protein 
(PrP) in prion therapeutics and to the 
discovery of a window of reversibility of 
early neuronal damage in prion disease. 
It introduces RNA interference (RNAi) 
and its therapeutic use in this context and 
discusses insights into prion pathogenesis 
and future treatment strategies and goals. 
A key concept is targeting the critical 
brain regions for the spread of prion rep-
lication. This may have relevance in other 
neurodegenerative diseases due to protein 
misfolding, which recent literature sug-
gests may also propagate throughout the 
brain in disease-specific patterns.
Prion Diseases: Background and 
Pathogenesis
Prion diseases, or transmissible spongiform 
encephalopathies, are fatal, neurodegen-
erative diseases that include Creutzfeldt-
Jacob disease (CJD) and kuru in humans, 
scrapie in sheep and bovine spongiform 
encephalopathy (BSE) in cattle. They are 
transmissible within and between mam-
malian species and are unique in having 
sporadic, inherited and acquired origins.
Central to prion pathogenesis is the 
conversion of a host-encoded prion pro-
tein, PrPC, into a partially-protease resis-
tant isoform, PrPSc, which accumulates in 
the brain and is associated with infectivity. 
The ability of transmission to be effected 
both naturally and experimentally by 
disease-associated prion protein, in the 
absence of associated nucleic acid, led 
to the ‘protein only hypothesis’ of prion 
propagation and infectivity.2 The con-
version process is self-propagating, with 
PrPSc acting as a conformational template 
recruiting PrPC for further conversion. The 
conversion reaction itself is critical to neu-
rotoxicity in prion diseases: neither loss of 
PrPC function,3-5 nor deposition of PrPSc 
is sufficient to cause pathology. However, 
the precise identity of the neurotoxic prion 
species and the exact mechanism of neu-
rotoxicity are unknown. Key pathological 
features of prion disorders, in addition 
to the aggregation of PrPSc (often in the 
form of amyloid plaques), are spongiform 
degeneration of neurons, astrocytosis and 
neuronal loss.
Prion diseases in humans are rare, 
with an overall incidence of ~1/million 
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and impaired synaptic transmission in the 
hippocampus, which recovered just one 
week after neuronal PrP depletion had 
occurred.29 The link between spongio-
sis and synaptic loss is not clear, but may 
reflect a stage of functional impairment of 
synapses before they are physically lost. 
The recovery of early spongiform change 
supports the concept that the early stage 
of disease represents a window when prion 
diseased neurons can be rescued. The early 
stage of synaptic dysfunction may be the 
‘window’ here, which is further supported 
by the findings of White and co-workers, 
discussed below.
Using RNAi for Therapeutic Gene 
Knockdown
Transgene-mediated reduction of PrPC 
expression does not offer direct thera-
peutic possibilities in human patients. 
Potential treatments aimed at removing 
PrPC must be achievable using extrinsic 
means. Recent developments in the field 
of RNA interference (RNAi) offer new 
opportunities to achieve such therapeutic 
gene silencing in vivo.
RNAi is a naturally occurring, highly 
conserved, sequence-specific mechanism 
for post-transcriptional gene silencing in 
eukaryotes. It is initiated by the presence 
of double-stranded RNA (dsRNA), which 
is exogenously introduced to the cell such 
as viral RNA, or endogenously encoded 
such as microRNAs (miRNAs) that regu-
late gene expression. Exogenously intro-
duced dsRNA is recognized by Dicer, 
a cytoplasmic ribonuclease that cleaves 
it into 21–23 nt sequences called short 
interfering RNAs (siRNAs).30 Both siR-
NAs and miRNAs interact with a multi-
protein RNA-induced silencing complex 
(RISC) that unwinds the RNA duplex 
and destroys one of the strands, known 
as the “passenger” strand.31 The remain-
ing “guide” strand is used as a template 
to localize cellular mRNAs containing 
a homologous sequence. The degree of 
homology between the guide strand and 
the mRNA determines whether RISC 
initiates endonucleolytic cleavage or 
translational arrest of the target mRNA, 
thereby silencing expression of that gene. 
Generally, siRNAs mediate destruction of 
target mRNAs whereas miRNAs silence 
altered intrinsic properties of specific cell 
types, detectable electrophysiologically,21 
and reported alterations of circadian 
rhythms.22 Depletion of PrPC in adult 
mice by transgene mediated deletion of 
PrP produces no further phenotypic con-
sequences and effectively excludes loss of 
PrPC function as a central mechanism in 
prion-mediated neurodegeneration.5
Proof of principle of the validity of 
strategies targeting PrPC came from the 
use of the adult onset model of PrPC deple-
tion. Transgenic animals in which PrP was 
depleted in neurons at nine weeks of age 
provided a system for testing the effects 
of PrP depletion in prion infection. PrP-
expressing mice were infected with prions 
at one week of age, eight weeks prior to 
transgene mediated PrP depletion. Prion 
infection was allowed to develop over this 
time, with establishment of early spongi-
form change, astrocytosis and PrPSc depo-
sition by the time neuronal PrP knockout 
occurred. This transgene mediated 
removal of neuronal PrPC during estab-
lished prion infection allowed the animals 
to survive long term without symptoms 
and led to a reversal of early spongiform 
change. The animals were effectively 
clinically cured.12 Control animals with 
equivalent early pathology at eight weeks 
post infection (wpi) progressed to full 
prion neurodegeneration and death, just 
four weeks after the onset of PrP knockout 
in ‘treated’ animals.
Timing of Treatment: Rescuing 
Early Neuronal Dysfunction, a 
Window of Reversibility
Spongiform change and synapse loss pre-
cede neuronal loss in mouse scrapie.23 
Changes in species-typical behaviors also 
occur long before end stage motor symp-
toms24-27 and correlate with early loss 
of presynaptic terminals in the dorsal 
hippocampus.28 In other neurodegen-
erative disorders, such as Alzheimer and 
Huntington diseases, the loss of synapses 
precedes neuronal loss. Compromised 
synaptic function is proposed to underlie 
early symptoms and cognitive decline in 
these disorders.
In prion infected mice with PrP deple-
tion early spongiform change was associ-
ated with cognitive and behavioral deficits 
worldwide, but their unique biology has 
resulted in their being amongst the best 
understood of the neurodegenerative dis-
orders at a molecular level. Currently, there 
is no effective treatment for prion diseases 
and the recent evidence for prion spread 
through contaminated blood products,6-8 
the identification of a novel type of vCJD 
with a protracted incubation time,9 and 
the emergence of atypical strains of BSE 
in cattle10 re-emphasize the importance of 
continued research into therapies for this 
ongoing threat to public health.
Therapeutic Strategies in Prion 
Disease: Rationale for Targeting 
PrPC
Any successful therapy in prion disease 
should prevent the formation, or block 
the actions, of the neurotoxic species. 
While pathological changes are charac-
terized by, and infectivity is associated 
with, PrPSc there is no evidence for in vivo 
toxicity caused by PrPSc.11,12 The existence 
of subclinical disease states where high 
levels of PrPSc are present without clini-
cal symptoms13-15 also argue against its 
direct toxicity. Further, there are several 
inherited prion diseases in which PrPSc is 
not detected in significant amounts,16-18 
and the degree of PrPSc accumulation in 
specific brain regions does not necessarily 
correlate with clinical features. Expression 
of host PrPC is, however, essential for both 
prion propagation and pathogenesis: PrP-
null mice are resistant to prion disease and 
unable to replicate infectivity,3,4 disease 
incubation time is determined by PrPC 
expression levels,4,19 and prion neurotox-
icity is confined to PrP-expressing neural 
tissue.20 Thus the expression of host PrPC 
is necessary for prion-induced neurotox-
icity, suggesting the generation of a toxic 
intermediate form during prion conver-
sion, or possibly the toxicity of early oligo-
meric forms of PrPSc. Removing PrPC, the 
substrate for prion conversion, is therefore 
an appealing therapeutic target.
PrPC is highly conserved across species. 
Its physiological function is not well under-
stood and ablation of PrPC is surprisingly 
well tolerated in vivo, at least in laboratory 
mice. Thus PrP-null mice are essentially 
normal phenotypically and behaviorally 
with only very subtle changes, including 
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Knockdown of PrP by RNAi,54 and resul-
tant inhibition of PrPSc replication in cell 
culture, have been described55 and RNAi 
of PrP has been achieved in vivo: virally 
expressed RNAi has been used to reduce the 
levels of PrPC in goats, cattle56 and mice.57 
Transgenic mice generated by lentiviral 
transduction of embryos stably express 
anti-PrP shRNAs and have increased resis-
tance to prion infection due to resultant 
RNAi of endogenous PrP.57 Here, RNAi 
mouse models of spinocerebellar ataxia,48 
Huntington disease49-51 and Amyotrophic 
lateral sclerosis (ALS).52,53
Therapeutic Use of RNAi in Prion 
Disease
The first therapeutic use of lentivirally 
mediated RNAi against prion protein was 
demonstrated in mice with established 
prion infection by White and co-workers.1 
gene expression through translational 
repression due to their imperfect comple-
mentarity to the target mRNA.32-34
When using RNAi as a biological tool, 
interfering RNA sequences can be designed 
to enter the RNAi pathway at various 
points. siRNA duplexes can be synthe-
sized for direct loading into RISC with-
out requiring further processing.35 This 
approach has the advantage of bypassing 
cellular defence mechanisms for recogni-
tion of long viral dsRNA, but unmodi-
fied siRNAs are typically unstable in vivo 
and cannot cross the blood-brain-barrier 
unaided. Targeting of brain structures 
has been achieved successfully with infu-
sion of naked siRNA duplexes alone36,37 in 
conjunction with transfection reagents38-42 
and conjugated to a peptide derived from 
the rabies virus glycoprotein.43 Whilst 
promising results have been attained, cur-
rent technologies mean clinical translation 
for treatment of many neurodegenerative 
diseases would require continuous or 
repeated long-term infusion of the inter-
fering RNA directly to the CNS.
Alternatively, stable, long-term expres-
sion of interfering RNA sequences can be 
achieved through the use of recombinant 
viral vectors (see schematic in Fig. 1). In 
this approach, siRNAs are expressed as 
short hairpin RNA (shRNA) stem-loop 
structures usually driven by RNA poly-
merase III promoters.44,45 As the shRNAs 
are expressed in the nucleus, they mimic 
pre-miRNAs ready for processing by 
Dicer.
For efficient delivery of shRNA-
expressing vectors to neuronal cells in 
vivo, recombinant viruses, including ret-
roviruses, adenoviruses, adeno-associated 
viruses and herpes-simplex viruses have 
all been harnessed. Retroviruses are com-
monly used due to their relatively low 
immunogenic potential and their abil-
ity to integrate into the host genome to 
facilitate stable expression. Lentiviruses 
are of particular use in the CNS as they 
are able to transduce and integrate into 
the genome of post-mitotic cells such as 
neurons and yield long-term expression of 
shRNAs in neurons when delivered intra-
cerebrally.46,47 Virally mediated RNAi has 
been used successfully as a therapeutic 
treatment in models of a number of differ-
ent neurodegenerative diseases, including 
Figure 1. Schematic representing virally mediated rnAi. A viral vector expresses shrnA  
sequences. these are processed by dicer and the anti-sense or guide strand is loaded into riSc 
for targeting of a specific mRNA, which is then degraded.
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neurons from degeneration, reduced PrPSc 
deposition and spongiosis (Fig. 2), and 
resulted in significantly increased survival 
of the animals (Fig. 3). Thus RNAi-treated 
animals were protected against developing 
the first behavioral deficits associated with 
early pathology of the CA1 region: loss 
of burrowing activity and object recogni-
tion memory. Morphologically, there was 
significantly less spongiform degeneration 
and neuronal loss where anti-PrP lenti-
virus was delivered compared to mock 
treated animals, suggesting sustained focal 
protection against neurotoxicity where 
allowing comparison of therapeutic effi-
cacy of lentiviral mediated RNAi with the 
effects of adult onset Cre-mediated PrPC 
depletion in prion infection. Transgenic 
mice overexpressing PrPC were inoculated 
with mouse-adapted scrapie and allowed to 
incubate the disease for 8 weeks until early 
neuropathology was established. They 
then received a single injection of lentivi-
rus expressing an shRNA targeting PrPC 
into each hippocampus. This treatment 
prevented the onset of early behavioral and 
cognitive deficits associated with this stage 
of prion infection, protected hippocampal 
of PrP is due to genetic engineering and 
is not a treatment. Importantly, however, 
this model confirmed the safety and lon-
gevity of stably expressed shRNAs against 
PrP in vivo, and the increased resistance 
of the chimeric animals generated to prion 
infection give additional insights into tar-
geting prion therapies, which is further 
discussed below.
White and colleagues have now used 
lentivirally mediated RNAi of PrP as an 
actual treatment. They essentially ‘rep-
licated’ their earlier experiments with 
the transgene mediated PrP depletion, 
Figure 2. Lentivirally mediated rnAi of PrP expression protects against prion neurodegeneration in vivo. Prion infected mice are treated either with 
bilateral hippocampal injections of LV-empty (blue) or LV-anti PrP (red) eight weeks post infection. representative images of neuroprotective effects 
of virally mediated PrP knockdown: (A) LV-anti PrP treatment protected against neuronal loss and reduced spongiform degeneration in cA1-3 regions 
(right hand) as compared to LV-empty treatment (left hand), which did not. (the right hippocampus is shown for all mice). (B) mice were infected with 
rmL prions at one week of age (black arrow) and tested for their ability to actively displace (burrow) food pellets from a tube. mice were treated 
with either LV-anti PrP or LV-empty at eight weeks post infection (colored arrows). LV-anti PrP treated mice (red bars) continued to actively burrow, 
whereas both untreated (grey bars) and LV-empty treated mice (blue bars) lost burrowing behavior, characteristic of prion infection at this stage.
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and it is likely that regional variations also 
affect prion replication rates and incuba-
tion periods. Further, prion diseases exist 
in different strains, which differ in their 
clinical and pathological profiles, as well as 
in the biochemical conformation and gly-
cosylation pattern of associated PrPSc. The 
pattern of PrPSc deposition throughout the 
animals, compared to mock- or untreated 
mice, with a mean increase in lifespan of 
23.5% compared to untreated animals.
The increased survival in RNAi treated 
mice is strikingly large with respect to the 
very small volume of brain targeted. Prion 
incubation times are inversely propor-
tional to overall levels of PrP expression,4,11 
PrP knockdown occurred. Interestingly, 
spongiosis was also reduced beyond the 
site of lentiviral injection—in thalamus 
and cortex (reviewed in ref. 1). PrPSc 
accumulation was lower in animals with 
virally mediated RNAi of PrP in the hip-
pocampus than in mock treated animals, 
and again this reduction was seen beyond 
the hippocampus in thalamus and cor-
tex. These more widespread changes 
throughout the brain are likely to reflect 
altered spread of prion infection after hip-
pocampal PrP knockdown. Of note, PrPSc 
accumulation—albeit at lower levels than 
in control animals—did not appear to 
affect neuronal function or cell survival, 
as reflected in preservation of hippocam-
pal behaviors and structural neuronal 
integrity. This is consistent with obser-
vations in mice with transgene mediated 
PrP depletion, and has implications for the 
level of knockdown required for therapeu-
tic effect. Thus simply slowing the rate of 
prion replication—here by reducing PrPC 
levels—may be effective for prevention of 
neurotoxic effects.
Additional Insights: Timing of 
Treatment and Strain-Driven  
Targets?
The critical advance is the effect of this 
treatment on survival of prion-infected 
mice (Fig. 3). A single treatment with 
focal injection of virus resulted in signifi-
cantly prolonged survival time of treated 
Figure 3. treatment with anti-PrP shrnA expressing lentivirus prolongs survival in mice with 
established prion disease. mice were infected with rmL prions at 1 week of age and were treated 
with bilateral hippocampal injections of either LV-anti PrP (n = 22) or LV-empty (n = 18) at 8 wpi 
or with no virus (n = 18). rmL-infected mice treated with no virus or with LV-empty died within 
91 and 101 days post infection (dpi) respectively; mice treated with LV-anti PrP survived longer, liv-
ing up to 129 dpi. (p < 0.0001 Student’s t test, 2 tails, compared to both LV-empty and untreated 
mice). the difference in survival among LV-anti PrP treated mice may be the result of timing of len-
tiviral injection. the earliest treated mice survived up to 50% longer (circled) than those injected 
later. (reprinted with permission: white et al. PnAS uSA 2008; 105:10238–43).
Figure 4. distribution of PrPSc over time in rmL-infected tg37 mice. PrPSc staining of rmL infected tg37 mice shows that the hippocampus is the main 
focus of accumulation of PrPSc prion replication at early and mid-stage prion infection. there is widespread deposition of PrP throughout the brain 
when mice are terminally ill at 12 wpi. (reprinted with permission: Suppl. data, white et al. PnAS uSA 2008; 105:10238–43).
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‘spread’ of tau or Alzheimer pathology in 
human brains over time and brain region 
is well recognized.66 Stopping protein 
propagation in its tracks with localized 
treatments may be an option worth con-
sidering in other human neurodegenera-
tive proteinopathies.
Implications for Therapy in  
Human Prion Diseases
A significant advantage of the RNAi 
therapeutic approach in prion disease is its 
applicability to all known strains of prion 
disease. Within any species the primary 
sequence of PrPC, and PrPSc, is the same 
for all strains: thus RNAi should be an 
effective treatment for all variants. This 
is in contrast to many previous candidate 
treatments for prion disease, which have 
suffered from inconsistent results depen-
dant upon the prion strain involved. This 
should also apply to familial prion dis-
eases that arise from a coding mutation 
in the gene encoding PrPC, PRNP. It is 
likely that allele-specific silencing strate-
gies to reduce expression of the mutant 
would be effective here. Genetic testing 
can identify these patients during the pre-
clinical phase so successful treatment of 
this category may be possible through pre-
ventative silencing of the mutant PRNP 
allele expression prior to development of 
pathology.
A further category of prion disease 
patients that may benefit from RNAi-
mediated silencing of PrPC are those indi-
viduals known to have been peripherally 
infected, such as recipients of contami-
nated blood products. Reduction of PrPC 
expression in organs that are crucial for 
prion replication and spread, such as the 
spleen and bone marrow (reviewed in ref. 
68), may significantly prolong the incu-
bation period. This could be achieved 
through regular systemic infusions of 
modified siRNA duplexes to lower PrPC 
levels sufficiently to prevent accumula-
tion of PrPSc above the cellular threshold 
for clearance, or for longer-term reduc-
tion of PrPC, through systemic delivery of 
VSV-G pseudotyped lentiviruses which 
can efficiently transduce these organs.69,70 
Selective targeting of routes of neuroinva-
sion such as the sympathetic nerves within 
the vertebral column may also significantly 
‘Taking out’ hippocampal prion rep-
lication in this model may have dispro-
portionate effects on survival as the focus 
of replication is removed, or significantly 
reduced. Interestingly, targeting other 
brain regions by lentiviral injection in the 
same model at the same time point had 
no significant effect on survival, unless 
the hippocampus was also targeted. Thus 
thalamic or striatal injections of anti-
PrP lentivirus had no therapeutic benefit 
on survival, but targeting either of these 
regions along with the hippocampus 
showed similar increases on survival as 
targeting the hippocampus alone (data not 
shown). The findings again speak to the 
concept of critical areas of prion replica-
tion, which likely vary with different prion 
strains, but may be key in guiding future 
therapy.
Either earlier intervention is exerting 
its effects through interference with the 
kinetics of prion replication, or it is act-
ing at a critical period in neuronal death 
‘routines’, or both. Clearly, all animals 
succumb eventually, presumably due to 
prion-mediated neurodegeneration in 
other, critical, brain regions, but the neu-
roprotective effects seen within the hip-
pocampus and beyond are undoubtedly a 
desirable effect of therapy. If transduction 
were to be more widespread, for example 
by pseudotying lentiviruses with coat pro-
teins that allow retrograde transport,60,61 
or by using evolving mechanical tech-
niques for enhanced delivery,62-64 more 
extensive neuroprotection and longer 
survival might ensue. Yet given the size of 
the human brain, perhaps a more focused, 
localized approach to key areas is a more 
realistic goal for therapy.
Finally, it appears that the concept of 
containing ‘spread’ of disease may well 
apply in protein folding neurodegenera-
tive disorders beyond prion diseases. A 
recent paper from Clavaguera et al. shows 
transmission and spread of tauopathy in 
transgenic mouse brains.65 Mutant tau 
mouse brain extract injected into wild-
type tau expressing mouse brains resulted 
in a spreading tauopathy in recipient ani-
mals. The authors further suggest that dif-
ferent tau mutations and isoforms might 
represent different strains of tauopathy, 
with diverse clinical and pathological 
manifestations. Indeed the evolution or 
brain is generally strain specific.58,59 The 
hippocampus is a focus of early prion rep-
lication and PrPSc deposition for the RML 
prion strain used here (Fig. 4): this local-
ized knockdown may therefore eliminate a 
key area for early prion replication in this 
model.
Further, if the survival curve for LV 
anti-PrP treated mice is examined closely, 
it is clear the effect of treatment on surv-
ival prolongation ranges from 0 to ~50%. 
This may in part be due to variation in 
neuronal transduction by virus in indi-
vidual mice, but likely also reflects differ-
ences in timing of therapy: mice treated 
earlier survived longest. Analysis of sur-
vival times showed that animals surviv-
ing longest (survival time up by nearly 
50% compared to controls, up to 129 
days post inoculation, (dpi)) had been 
treated a mean of 52 dpi, whereas animals 
surviving least after treatment (as little as 
87 dpi) had been injected a mean of 58 
days post inoculation. Anticipating treat-
ment by a few days here has a dramatic 
effect on survival. This may reflect a crit-
ical window for neuronal rescue in terms 
of a neurons’ own program of death, or 
be dependent on the kinetics of prion 
spread, reflecting the fact that interven-
tion needs to be accurately timed. This 
introduces the concept that treatment of 
prion diseases is likely to be most effec-
tive if we understand in detail the pat-
terns of prion spread and replication for 
particular strains. This idea is supported 
by the observation that the degree of chi-
merism in mice transgenic for an shRNA 
targeting PrPC expression did not always 
correlate with the survival time following 
prion infection. Some mice with only 20% 
chimerism survived as long as others that 
were 90–95% chimeric (see Pfeifer et al. 
Suppl. data).57 It would be interesting to 
correlate the regions in which PrP expres-
sion is reduced in the different chimeric 
models with the effect on incubation 
time in the shRNA transgenic mice also. 
If this were to correlate with hippocam-
pal knockdown (Pfeifer and co workers 
also used RML prions) the concept of 
therapy targeted to key replication areas 
would be further strengthened. Further 
the resistance of different chimeric lines 
to other prion strains would be interest-
ing to compare.
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proceed with caution and the use of tran-
sient silencing through infusion of siRNA 
duplexes or expression of shRNAs from 
inducible viral vectors should be consid-
ered so that treatment can be halted if 
unforeseen adverse effects develop. In the 
end, the balance of possible adverse effects 
of PrP loss against the benefits of improved 
survival and protection against neuronal 
loss in key brain areas, will determine 
future therapies for prion and other neu-
rodegenerative disorders.
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